Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Z165
- Development stage
- Unknown
- Lead developer
- Jiangxi University of Traditional Chinese Medicine
01
Overview
Z165: sourced facts only. name: "Two lead compounds among these derivatives, Z165 and Z168 displayed IC50 values of 0.44 μM and 3.23 μM against butyrylcholinesterase, suggesting their promising potential for further structural optimization." [PMID:40318509]; target: "Two lead compounds among these derivatives, Z165 and Z168 displayed IC50 values of 0.44 μM and 3.23 μM against butyrylcholinesterase, suggesting their promising potential for further structural optimization." [PMID:40318509]; developer: "Shenyang Pharmaceutical University, School of Traditional Chinese Materia Medica, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China; National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang 330006, PR China." [PMID:40318509]
02
Targets
Butyrylcholinesterase
Beyond the preview
Go deeper on Z165.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Z165.